LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

West Pharmaceutical Services Inc

Închisă

SectorSănătate

276.48 -1.52

Rezumat

Modificarea prețului

24h

Curent

Minim

275.56

Maxim

277.44

Indicatori cheie

By Trading Economics

Venit

8.2M

140M

Vânzări

38M

804M

P/E

Medie Sector

40.651

79.874

EPS

1.96

Randament dividend

0.31

Marjă de profit

17.406

Angajați

10,600

EBITDA

19M

217M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+26.13% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.31%

2.31%

Statistici piață

By TradingEconomics

Capitalizare de piață

-56M

20B

Deschiderea anterioară

278

Închiderea anterioară

276.48

Sentimentul știrilor

By Acuity

50%

50%

168 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

West Pharmaceutical Services Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 nov. 2025, 16:49 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov. 2025, 15:32 UTC

Achiziții, Fuziuni, Preluări

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov. 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov. 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 nov. 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov. 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov. 2025, 15:54 UTC

Achiziții, Fuziuni, Preluări

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov. 2025, 15:44 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov. 2025, 15:43 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov. 2025, 15:42 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov. 2025, 15:41 UTC

Achiziții, Fuziuni, Preluări

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov. 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov. 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov. 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov. 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 nov. 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov. 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov. 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27 nov. 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov. 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov. 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27 nov. 2025, 11:07 UTC

Câștiguri

Genting: Positive About Prospects Over Longer Term

27 nov. 2025, 11:06 UTC

Câștiguri

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov. 2025, 11:04 UTC

Câștiguri

Genting: International Travel Demand Expected to Remain Resilient

27 nov. 2025, 11:04 UTC

Câștiguri

Genting: Global Growth Expected to Remain Subdued

27 nov. 2025, 11:04 UTC

Câștiguri

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov. 2025, 10:59 UTC

Câștiguri

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov. 2025, 10:58 UTC

Câștiguri

Genting Bhd 3Q Rev Rose 14% on Year

27 nov. 2025, 10:56 UTC

Câștiguri

Genting Bhd 3Q Net MYR30.3M

27 nov. 2025, 10:56 UTC

Câștiguri

Genting Bhd 3Q EPS MYR0.0079

Comparație

Modificare preț

West Pharmaceutical Services Inc Așteptări

Obiectiv de preț

By TipRanks

26.13% sus

Prognoză pe 12 luni

Medie 349.56 USD  26.13%

Maxim 375 USD

Minim 311 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruWest Pharmaceutical Services Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

10

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

213.26 / 219.27Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

168 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat